Cannabis Edibles for Tourette Syndrome: What the Trials Actually Show

Tourette syndrome is one of the few conditions on this site where the best cannabis trials were swallowed rather than smoked or sprayed. Kirsten Müller-Vahl's oral THC in Hannover and the Australian 1:1 THC:CBD oil that Philip Mosley's team tested in 2023 are, in pharmacological terms, edibles with a lab coat on: they pass through the gut and the liver, they peak at two to three hours, and they last four to eight.

So the position here is narrow and specific. For adults whose tics are severe and have not responded to behavioural therapy or standard drugs, a slowly titrated 1:1 oral product has the best support of anything sold in a dispensary. That support is small: three randomized oral trials with 58 people between them, all positive in some form. The largest trial, CANNA-TICS, 97 adults on the nabiximols spray, missed its primary endpoint. The European guideline still lists cannabis-based medicines among the reasonable choices for treatment-resistant cases, which is more than most conditions on this site can say. The evidence is thin, and it points one way. Children are a different matter, covered at the end, and the short version is case reports and nothing else.

Does cannabis help Tourette tics?

In small trials of adults with severe tics, mostly yes. The 2023 Mosley crossover found a 1:1 THC and CBD oil cut tic scores by 8.9 points against 2.5 on placebo, and two German THC trials were positive. The largest trial, CANNA-TICS, missed its primary endpoint, and no trial has tested children.

The Mosley trial is the one to read. Twenty-two adults with severe Tourette, eight of them women, took six weeks of an oral oil holding 5 mg/ml of THC and 5 mg/ml of CBD and six weeks of placebo, in random order, with a four-week washout between. On the Yale Global Tic Severity Scale, which scores tics from 0 to 50, the active period lowered the total tic score by 8.9 points (±7.6) by week six against 2.5 (±8.5) on placebo, and the treatment-by-visit interaction was significant (P=0.008). Tic scores also tracked blood levels of a THC metabolite, a link the authors note weakened once one outlier was removed.

Müller-Vahl's two trials came twenty years earlier and used THC alone. In 2002, twelve adults each took a single dose of 5, 7.5 or 10 mg against placebo, and self-rated tics improved (p=0.015). The detail that matters for anyone holding a gummy is the blood work: tic improvement correlated with peak levels of 11-hydroxy-THC, the metabolite the liver makes when THC is swallowed. The 2003 follow-up ran 24 adults for six weeks on up to 10 mg a day and found significant differences or trends on several examiner scales. Seven of the 24 dropped out or were excluded, only one for side effects.

The one trial of inhaled cannabis is the useful contrast. In Abi-Jaoude's 2023 Toronto crossover, twelve adults, nine of whom finished, inhaled a single vaporized 0.25 g dose of 10% THC flower, a 9% THC and 9% CBD flower, a 13% CBD flower and placebo, two weeks apart. None beat placebo on the primary video tic rating. The 10% THC product beat placebo on urges, distress and the clinician's global impression, the balanced product did so to a lesser degree, and the THC-only product produced the most cognitive and psychomotor side effects. Most participants could tell whether they had been given cannabis, which is the standing problem with blinding any THC trial.

The honest counterweight comes from the guideline itself. When the European panel wrote its 2022 update, it cited a meta-analysis of the two small randomized THC trials then available, 41 people combined, that found no significant benefit over placebo. Mosley's trial was published after that, and it is the strongest single result the field has.

Why did the largest trial miss its endpoint?

CANNA-TICS randomized 97 adults, two to one, to nabiximols or placebo for 13 weeks, and set a responder bar of at least a 25% drop in tic score. On nabiximols 21.9% cleared it (14 of 64) against 9.1% on placebo (3 of 33), and the authors wrote that superiority "could formally not be demonstrated."

More than twice the response rate and still a miss: a responder cut-off in a trial this size leaves little room. The secondary analyses showed trends for tics, depression and quality of life, and exploratory subgroups (men, people with more severe tics and people with comorbid ADHD) did better. Subgroup results like those are hypotheses for the next trial. Nabiximols is the same roughly 1:1 THC:CBD spray, sold as Sativex, that runs through our MS spasticity page, and it is sprayed into the mouth, which puts it a step away from an edible. The oral trials are still the ones that transfer.

Is THC or CBD better for Tourette syndrome?

THC does the work on tics. Every positive trial contained it, and in the only study to test a CBD-dominant product, tic and urge scores tracked blood levels of THC and its metabolites, not CBD. CBD is in the 1:1 oil because Mosley's team cited early evidence that it improves THC's side-effect profile.

What dose did the Tourette trials use?

Mosley started at 1 ml of oil a day, 5 mg THC and 5 mg CBD, and added 1 ml a week depending on tic scores, to a ceiling of 4 ml in divided doses: 20 mg of each. Müller-Vahl's 2003 trial stopped at 10 mg THC a day. Both ran six weeks, by mouth.

Those are protocol details from the trial registry and the papers, not instructions. For context, our dosing guide sets the low tier at 2.5 to 5 mg and the moderate tier at 5 to 15 mg, so Mosley's starting dose sits at the top of low and its ceiling lands in the high tier, reached over weeks. Anyone below the starting step is in the range our microdosing guide covers. Timing matters with divided doses: per our guide to how long edibles last, a swallowed dose starts working in 30 minutes to 2 hours and peaks at 2 to 3 hours.

Three products from our existing cluster pages come closest to the trial ratio, each checked on its brand site on October 14, 2026:

The Petra mint is the closest match to the trial oil, equal parts THC and CBD in a 2.5 mg unit, and Kiva's own directions say to start with one mint and wait two hours for full effect. The arithmetic is less charming. Mosley's 1 ml starting step is two mints, every weekly step adds two more, and the 20 mg ceiling is eight mints a day, so a 40-mint tin lasts five days at the top dose. It is a precise road to the trial dose and a slow one, sold in four states.

Wyld Peach suits someone who finds THC hard going, since each gummy carries twice the CBD. At the trial's THC ceiling that is 40 mg of CBD a day, double what Mosley used, and a ten-gummy tin lasts two and a half days. The Papa & Barkley gummy matches the 1:1 core and adds 5 mg of CBG that nobody has tested in tics; it is along for the ride. The version Papa & Barkley ships direct is a hemp product, labelled "less than 0.3% THC" on a package holding 100 mg of it, which is a statement about the weight of the gummies and says nothing about the dose. At 100 mg of THC a package that version is far over the 0.4 mg per-container cap that takes effect on December 11, according to our hemp ban page. The table links the California-licensed version sold in dispensaries, which sits outside the hemp rules.

Can edibles help the anxiety and OCD that come with Tourette?

There are signals and no proof. Mosley's trial reported possible reductions in anxiety and obsessive-compulsive symptoms as secondary outcomes, and the 2002 single-dose THC study saw self-rated obsessive-compulsive behaviour improve (p=0.041). No trial has made either the main question, and THC at higher doses can make anxiety worse.

The comorbidities are the rule rather than the exception. In Hirschtritt's 2015 study of 1,374 people with Tourette, 85.7% had at least one lifetime psychiatric diagnosis, 72.1% met criteria for OCD or ADHD, and roughly three in ten had a mood disorder, an anxiety disorder, or oppositional and conduct problems. CANNA-TICS saw a trend on depression. For anxiety in particular, the dose curve on our generalized anxiety page is the one to respect: 7.5 mg of THC reduced stress in trial, and 12.5 mg increased it. A titration aimed at a 20 mg tic dose passes straight through that line.

Is cannabis safe for kids with Tourette?

Nobody knows, because no controlled trial has enrolled children. The paediatric evidence is case reports: a 15-year-old boy treated with oral THC in 2010, and two boys followed for five and six years in a 2025 report. This page makes no product or dose suggestion for anyone under 21, and the treating neurologist is the person to ask.

Both reports describe good outcomes, and both are single cases from specialist clinics. In Hasan's 2010 case, THC improved the tics enough that the boy could take a stimulant for his ADHD. In the 2025 report from Müller-Vahl's group, the boys started at eight and twelve. One moved from pure THC to an oral THC-dominant extract at 12.5 to 15 mg a day, and the other had been given vaporized THC flower from the start by his parents, both physicians, at an estimated 48 to 144 mg of THC a day. That is a case report, and it is also a reminder of how far outside any trial the real world already runs.